Chordoma Foundation

Scientific Advisory Board

Our Scientific Advisory Board (SAB) is comprised of leading chordoma researchers, as well as experts in related fields, including cancer genetics and drug development. The SAB identifies priorities for advancing the development of treatments for chordoma and shapes the Foundation’s research roadmap.

David-Drewry-SGC-400x400

David Drewry, PhD

David Drewry is an expert in medicinal chemistry and drug discovery, with a special interest in protein kinases. For 24 years he worked in drug discovery at GlaxoSmithKline (GSK), where he led teams across the preclinical spectrum of drug discovery. His research interests include the art and science of medical chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks, and precompetitive chemical biology to facilitate target identification. Since leaving GSK, David became a founding member of the Structural Genomics Consortium at the University of North Carolina. In addition, he is currently the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule kinase inhibitors for the treatment of cancer.

Adrienne Flanagan, MD, PhD

Dr. Flanagan is Professor of Musculoskeletal Pathology at the University College London and Clinical Lead and consultant histopathologist at the Royal National Orthopaedic Hospital in Stanmore. She runs an active research program on bone cancer, and has made seminal discoveries about the molecular biology and genetics of chordoma. She collaborates with the Wellcome Trust Sanger Institute on the Chordoma Genome Project and is co-PI on the International Cancer Genomics Consortium bone cancer initiative.

Fran Hornicek, MD, PhD

Dr. Hornicek is Professor in the Department of Orthopaedic Surgery at Harvard Medical School and Chief of the Orthopaedic Oncology Service at MGH, where he has one of the nation’s largest surgical practices for chordomas. He is also Co-Director of the Center for Sarcoma and Connective Tissue Oncology and director of the Stephan L. Harris Center for Chordoma Care at MGH. In these roles he leads a coordinated, cross-disciplinary chordoma research effort at MGH.

Michael Kelley, MD

Dr. Kelley is Associate Professor of Medicine at Duke University and Chief of Hematology and Oncology at the Durham VA Medical Center. His lab has a major focus in chordoma, and in collaboration with colleagues at the National Cancer Institute has identified brachyury as a cause of familial chordoma.

Paul Meltzer, MD, PhD

Dr. Meltzer is a medical oncologist and Chief of the Genetics Branch of the Center for Cancer Research at the National Cancer Institute. He is regarded as a leading expert in cancer genomics, and has led major genomic profiling projects for multiple tumor types including sarcomas, melanoma and breast cancer.

Deric Park, MD

Dr. Park is Assistant Professor in the Department of Neurological Surgery at the University of Virginia, where he provides medical care for patients with brain tumors and directs the Laboratory of Brain Tumor Biology. He serves as principal investigator of a multi-center clinical trial for chordoma, and his research aims at developing novel treatments for chordoma.